Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported that its investigational gene therapy UX111 demonstrated sustained cognitive improvements and significant biomarker gains in long-term follow-up from two…
February 09, 2026
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported that its investigational gene therapy UX111 demonstrated sustained cognitive improvements and significant biomarker gains in long-term follow-up from two…